.png){kind=icon}
返回
Complement Profiling in Glomerular Disease
.png){kind=icon}
PRE
AI
DOI：10.2215/CJN.0000000943.png)
.png){kind=icon}
原文求助.png){kind=icon}
分享.png){kind=icon}
收藏
摘要
En 中文
Complement activation occurs in most glomerular diseases. Complement activation on the kidney biopsy is evidenced by deposition of C3c and C1q on the kidney biopsy. The kidney biopsy provides only limited information as other complement proteins and complement-regulating proteins are not typically studied. Furthermore, kidney biopsy does not distinguish between activated versus inactive complement proteins. Laser microdissection and mass spectrometry (LMD/MS) is a relatively new methodology that can provide an in-depth evaluation of the proteomic profile of complement proteins, complement regulating proteins, complement pathways, and can also determine whether active complement fragments are present in the kidney biopsy sample. A semiquantitative burden of complement can be determined. Furthermore, proteins of a disease can be analyzed using principal component analysis, volcano plots, and heatmaps. In this review, the complement proteomic profile of diseases representing the spectrum of glomerular diseases are shown. The proteomic complement profile of membranous nephropathy associated with various antigens, Ig-associated GN, such as proliferative GN with monoclonal Ig deposits and fibrillary GN, C3 glomerulopathy, and IgA nephropathy, are shown. The findings show important differences in the complement profile including pathways of complement in each disease, and even within the disease, such as altered complement burden and profile between different antigens associated with membranous nephropathy. In conclusion, LMD/MS is a valuable tool for determining the complement proteins, complement-regulating proteins, complement pathways, and determining the burden of complement in each individual case of glomerular disease. In the era of new anticomplement drugs, it will become essential to accurately determine the complement profile in each kidney biopsy for a personalized approach to treating the glomerular disease. LMD/MS is a methodology that can help provide such answers.
Keyword:
complement
glomerular disease
kidney biopsy
pathology
proteomics
期刊
IF:
7.1
论文数:
5.7K
被引数:
2.1W
机构
引用论文
Apolipoprotein E is enriched in dense deposits and is a marker for dense deposit disease in C3 glomerulopathy载脂蛋白E在致密沉积物中富集，是C3肾小球病致密沉积物疾病的标志物.png)
KIDNEY INTERNATIONAL
OAAI
KIDNEY INTERNATIONALIF12.6
OAAI分享收藏Contactin-1 is a novel target antigen in membranous nephropathy associated with chronic inflammatory demyelinating polyneuropathyKIDNEY INTERNATIONALOAAI
KIDNEY INTERNATIONALIF12.6
OAAI分享收藏Glomeruli of Dense Deposit Disease contain components of the alternative and terminal complement pathwayKIDNEY INTERNATIONAL
OAAI
KIDNEY INTERNATIONALIF12.6
OAAI分享收藏分享收藏Mayo Clinic/Renal Pathology Society Consensus Report on Pathologic Classification, Diagnosis, and Reporting of GN梅奥诊所/肾脏病理学会关于GN的病理分类，诊断和报告的共识报告OAAI
OAAI分享收藏
查看更多内容